Is there any alternative drug after resistance to serputinib/serpatinib?

Selpercatinib/Selpercatinib (Selpercatinib) is a targeted therapy drug that targets RET (rearrangement period transcription factor) gene mutations and is used to treat thyroid cancer and non-small cell lung cancer. However, due to individual differences and tumor complexity, patients may develop resistance to seputinib. When patients develop resistance to seputinib, they may need to look for other treatment options.

Before considering alternative drugs, doctors will first evaluate the patient's condition and cause, and conduct further genetic testing to determine the specific mechanisms leading to resistance. Currently, targeted therapeutic drugs targeting RET mutations are not limited to seputinib, and several other drugs are being studied or have been approved. For example, pralsetinib (also known as BLU-667) and vandetanib also target RET mutations and may serve as alternatives to seputinib in some cases. In addition, as medical research continues to advance, new RET-targeting drugs may become available. Therefore, when seppotinib resistance occurs, patients are advised to work closely with their physicians to learn about the latest treatment options and clinical trial opportunities.

Up to now, the original drug is sold in China as Seputinib, but it is not included in medical insurance. The price of each box of specifications80mg*56 capsules may be more than 10,000 yuan. There are European and American versions of the original drugs sold overseas, with the price of each box ranging from 20,000 to more than 100,000 yuan (prices may fluctuate due to exchange rates). There is also Seputinib overseasGeneric drugs are on the market, and their pharmaceutical ingredients are basically the same as those of original drugs sold domestically and abroad, such as the specifications produced by Laos Pharmaceutical FactoryThe price of each box of 40mg*120 tablets is more than 4,000 yuan (the price may fluctuate due to the exchange rate).